Get the Stockscreener App
448.28
0.24%
-1.09
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $448.28, with a volume of 1.67M.
It is down -0.24% in the last 24 hours and down -12.78% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$449.37
Open:
$446.8
24h Volume:
1.67M
Relative Volume:
0.79
Market Cap:
$166.59B
Revenue:
$45.20B
Net Income/Loss:
$6.87B
P/E Ratio:
24.65
EPS:
18.1888
Net Cash Flow:
$6.75B
1W Performance:
+2.27%
1M Performance:
-12.78%
6M Performance:
-23.69%
1Y Performance:
+11.94%
1-Day Range:
$444.41
$454.45
1-Week Range:
$435.27
$455.00
52-Week Range:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | DZ Bank | Buy |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-08-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Dec-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Thermo Fisher (TMO) director gets 499-share award, 80 withheld for tax - Stock Titan
Director at Thermo Fisher (NYSE: TMO) granted new shares - Stock Titan
Thermo Fisher (NYSE: TMO) director receives 499-share stock award - Stock Titan
Thermo Fisher (NYSE: TMO) director receives 499-share equity grant - Stock Titan
Thermo Fisher (TMO) director receives 499-share stock grant, now holds 2,602 - Stock Titan
Thermo Fisher (TMO) director Tyler Jacks receives 499-share stock grant - Stock Titan
Director at Thermo Fisher (NYSE: TMO) awarded 499 common shares - Stock Titan
Thermo Fisher (TMO) director Ruby R. Chandy receives 499-share stock grant - Stock Titan
Director at Thermo Fisher (NYSE: TMO) receives 499-share stock grant - Stock Titan
Nuvation Bio (NUVB) Collaborates with Thermo Fisher - Insider Monkey
What Thermo Fisher CEO Said at Investor Day That the Market Is Still Processing - TIKR.com
What Thermo Fisher Scientific (TMO)'s New Gothenburg Lab Expansion Means For Shareholders - Yahoo Finance
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County - PA Department of Community & Economic Development (.gov)
Automated Microbiology Market to Reach USD 13.50 Billion by 2033 - openPR.com
Thermo Fisher Scientific’s SWOT analysis: stock navigates growth amid strategic shifts - Investing.com
High-Throughput Screening (HTS) Market Research Report to 2032 - openPR.com
Thermo Fisher Scientific Announces Quarterly Dividend - The National Law Review
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Declares Consistent Dividend of $0.47 Per Share - GuruFocus
TD Cowen Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating - Moomoo
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day - BioSpace
Press Release: Thermo Fisher Scientific Announces Quarterly Dividend - Moomoo
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.47 a Share, Payable July 15 to Shareholders of Record on June 15 - marketscreener.com
Thermo Fisher Scientific Inc Investor Day Transcript - GuruFocus
Thermo Fisher Scientific Inc Annual Shareholders Meeting Transcript - GuruFocus
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation - PharmiWeb.com
Thermo Fisher (TMO) Showcases Growth Potential at Investor Day - GuruFocus
Thermo Fisher (TMO) Projects Steady Growth with Strategic Focus - GuruFocus
Thermo Fisher Scientific highlights industry leadership, growth outlook and long-term value creation at 2026 Investor Day - marketscreener.com
Thermo Fisher targets 7% organic revenue growth long-term - Investing.com
Thermo Fisher Expects 7% Annual Organic Revenue Growth Over Long Term - marketscreener.com
Thermo Fisher targets 7% organic revenue growth long-term By Investing.com - Investing.com Canada
Thermo Fisher Scientific : 2026 Investor Day - marketscreener.com
Thermo Fisher targets a $255B science market as AI reshapes drug discovery - Stock Titan
TMO Technical Indicators, RSI, MACD & Moving Averages - techi.com
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Stock Down 31% From Its 52-Week High Despite Raising Full-Year EPS Guidance. Here’s What Happened - TIKR.com
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - PR Newswire UK
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics - News-Medical
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - BioSpace
12% Of This Thermo Fisher Scientific Insider's Holdings Were Sold - Moomoo
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with Ne - PharmiWeb.com
Top Companies Driving Innovation In Specimen Bag Zip Closure Solutions - SNS Insider
Life Science Instrumentation Market Forecast Report - GlobeNewswire
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading - Yahoo Finance UK
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps - Yahoo Finance
12,952 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by North Dakota State Investment Board - MarketBeat
Do Wall Street Analysts Like Thermo Fisher Scientific Stock? - Yahoo Finance
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Unlocking a 39.52% Potential Upside with Robust Buy Ratings - DirectorsTalk Interviews
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone - Yahoo Finance
CHA Biotech, Thermo Fisher Partner to Build K-Bio CIC Research Hub - Seoul Economic Daily
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):